We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Regulatory and Other Rheumatoid Factors Analyzed in RA Patients

By LabMedica International staff writers
Posted on 06 Jan 2022
Print article
Image: The RF direct latex test for the detection of rheumatoid factor (RF) in serum (Photo courtesy of VedaLab)
Image: The RF direct latex test for the detection of rheumatoid factor (RF) in serum (Photo courtesy of VedaLab)
Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body.

Despite numerous studies, the only properties definitively established for rheumatoid factor (RF) are that RF is an antibody to the Fc portion of modified IgG, and that elevated RF levels are a diagnostic marker for RA. Both the mechanisms by which RF level is elevated in autoimmune and infectious diseases and the role that RF plays in healthy and disease states remain speculative.

Immunologists at the Udmurt State University (Izhevsk, Russian Federation) studied a total of 32 patients with an established diagnosis of rheumatoid arthritis. Of those, 22 patients had high to moderate rheumatoid arthritis activity. Several of the patients had systemic manifestations, such as anemia, rheumatoid nodules, Sjögren's syndrome. The duration of disease in the sample of RA patients studied was 2 to 20 years, with a mean of 8 ± 5.9 years and 35% of patients were receiving combination therapy.

The RF direct latex test (VedaLab, Alençon, France) was used to detect rheumatoid factor in the sera of arthritis patients. The regulatory rheumatoid factor (regRF) titer was determined in an agglutination test using human IgG-loaded tanned human erythrocytes. RegRF depletion from rheumatoid arthritis sera was also performed. Lyophilized human IgG was used to prepare an agglutination test system for detecting regRF. Size exclusion chromatography was performed using a Sephacryl S 100 26/400 column (Cytiva, Marlborough, MA, USA). A Genesys 10S UV-Vis Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) was used for the analysis.

The investigators reported that patients in remission had regRF levels higher than in healthy subjects. The regRF in remission was characterized by tight binding to its antigen, as in healthy subjects. The regRF levels in patients with active RA varied dramatically, and regRF binding to its antigen was weak. The exacerbation of Still's disease coincided with low regRF levels and affinity, while an improvement in patient condition was associated with an increase in regRF levels and affinity. The RF specific to RA, which was detected by the RF latex-fixation method, was a nonhomogeneous population of antibodies that included RF to lyophilized IgG, to IgG immobilized on polystyrene, and to rabbit IgG.

The authors concluded the RA remission is associated with an increase in regRF levels and affinity. Results of an analysis of a clinical case of Still's disease were consistent with the results obtained when patients with active rheumatoid arthritis were compared with those in remission. The study was published on December 24, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Udmurt State University
VedaLab
Cytiva
Thermo Fisher Scientific


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.